Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3147Neoplasms 2478Carcinoma, Non-Small-Cell Lung 1889Prostatic Neoplasms 1645Colorectal Neoplasms 1438Lung Neoplasms 1312Multiple Myeloma 940Neoplasm Metastasis 930Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 862Ovarian Neoplasms 815Melanoma 794Carcinoma, Hepatocellular 745Stomach Neoplasms 650Brain Neoplasms 643Recurrence 642Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 613Glioblastoma 575Lymphoma 551Uterine Cervical Neoplasms 549Triple Negative Breast Neoplasms 515Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 505Endometrial Neoplasms 467Hematologic Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 448Sarcoma 439Lymphoma, Non-Hodgkin 439

Interventions

Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gynecological Tumors × 1 year × Clear all
NCT06798207 2025-07-18

A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Recruiting
170 enrolled

Gynecological Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡